- Home
- PXED vs CVAC Comparison
PXED vs CVAC Comparison
Compare PXED & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PXED | CVAC |
|---|---|---|
| Founded | 1976 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PXED | CVAC |
|---|---|---|
| Price | $31.78 | $4.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $45.00 | $6.83 |
| AVG Volume (30 Days) | 142.8K | ★ 1.3M |
| Earning Date | 01-13-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 3.51 | 0.94 |
| Revenue | ★ $1,007,192,000.00 | $83,000,117.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $4.86 | $23.71 |
| P/E Ratio | $9.74 | ★ $4.98 |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $23.52 | $2.48 |
| 52 Week High | $47.08 | $5.72 |
Technical Indicators
Market Signals| Indicator | PXED | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.92 |
| Support Level | N/A | $4.26 |
| Resistance Level | N/A | $4.68 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 62.56 |
Price Performance
Historical ComparisonAbout PXED Phoenix Education Partners Inc.
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.